Skip to main content
Equibles
SUPN logo

SUPN · Supernus Pharmaceuticals, Inc.

Track SUPN — free

Use SUPN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$43.53 -0.44 (-1.00%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.56B
Shares
58.13M

SUPN metrics

72 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$43.53
Market cap
$2.56B

Price action

19 metrics
Price change (1W)
-0.5%
Price change (30D)
-6.9%
Price change (3M)
-2.7%
Price change (6M)
-19.2%
Price change (YTD)
-12.4%
Price change (1Y)
-4.2%
Trailing year
Price change (5Y)
+58.5%
52-week high
$57.00
52-week low
$43.25
Change from 52-week high
-23.6%
Change from 52-week low
+0.6%
Annualized volatility
35.6%
Beta
0.5
RSI (14D)
38.0
Price vs SMA 50
-6.7%
Price vs SMA 200
-10.2%
Avg volume (3M)
835,715
Relative volume
0.5
Average dollar volume
$38.64M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
58.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.1×
reciprocal yield 32.5%
P / book
2.5
reciprocal yield 40.3%
FCF yield
0.7%
TTM · current market cap
Buyback yield
—
P / FCF
136.0
reciprocal yield 0.7%
P / operating cash flow
128.4
reciprocal yield 0.8%
Earnings yield
-4.3%

Historical valuation

8 metrics
P / E historical average (3Y)
33.7×
reciprocal yield 3.0%
P / E historical average (5Y)
23.4×
reciprocal yield 4.3%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-22

Profitability

9 metrics
Gross margin
88.1%
Operating margin
-15.7%
Trailing 12 months
Net margin
-13.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$130.46M
Net income (TTM)
−$109.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.92
FCF margin
2.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$16.84

Growth

11 metrics
Revenue growth YoY
+32.4%
Year over year
Net income growth YoY
-359.4%
Revenue (TTM)
$830.44M
Trailing 12 months
EPS growth YoY
-352.5%
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+2.5%
Revenue CAGR (5Y)
+6.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-26.6%
FCF CAGR (5Y)
-19.4%

Quality

14 metrics
Return on equity
-10.7%
Return on assets
-7.7%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$33.25M
Free cash flow (TTM)
$18.79M
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$179.95M
Total assets
$1.43B
Total debt
$401.44M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$19.91M
Capital expenditures (TTM)
$1.12M
R&D (TTM)
$126.09M
SG&A (TTM)
$560.88M
Stock compensation (TTM)
$34.60M
R&D / revenue
15.2%
Stock compensation / revenue
4.2%

Ownership (13F)

3 metrics
13F filers
337
13F filer change QoQ
+7
Institutional ownership
103.9%

Short interest

3 metrics
Short interest
7.1%
Latest settlement · 2.8 days to cover
Days to cover
2.8d
Short-squeeze score
47 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1356576 CUSIP 868459108 13F (30d) 229 filings 226 filers Visit website Investor relations